Prognostic significance of PET/CT-derived metabolic heterogeneity indices in wild-type metastatic colorectal cancer
Öz
Purpose: Tumor heterogeneity is one of the important factors affecting treatment response in malignant diseases, and this heterogeneity can be estimated by positron emission tomography-computed tomography (PET/CT) metabolic parameters. This study aimed to evaluate the efficacy of intratumoral metabolic heterogeneity indices in predicting survival in patients with wild-type metastatic colorectal cancer (mCRC). Materials and Methods: This retrospective analysis included 79 patients with wild-type mCRC who were followed between 2018 and 2023 and who underwent PET/CT at the time of diagnosis for staging. The relationship between heterogeneity indices and survival and mortality was assessed. Results: The median heterogeneity index-1 (HI-1) value was higher in the non-survivor group compared to the survivor group, but did not reach a statistically significant level (3.32 vs. 2.91). The median heterogeneity index-2 (HI-2) value was also higher in the non-survivor group compared to the survivor group, and there was a statistically significant difference between the groups (10.36 vs. 7.65). The median overall survival (OS) of the patients was 42.2 (95% CI 28.9-55.5) months, and the median progression-free survival (PFS) was 19.6±3.9 months. Median OS was longer in patients with lower HI-2 (61.8±15.3 months vs. 33.9±5.2 months). Conclusion: Our findings support the potential of PET/CT-based calculated heterogeneity indices as a noninvasive prognostic marker in wild-type mCRC patients. In wild-type mCRC patients, HI-2 can be used to predict patients who will benefit less from treatment.
Anahtar Kelimeler
Kaynakça
- Islami F, Ward EM, Sung H, Cronin KA, Tangka FKL, Sherman RL et al. Annual Report to the Nation on the Status of Cancer, Part 1: National cancer statistics. J Natl Cancer Inst. 2021;113:1648.
- Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17-48.
- Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67:93-9.
- van Cutsem E, Nordlinger B, Cervantes A. Advanced colorectal cancer: ESMO clinical practice guidelines for treatment. Ann Oncol. 2010;21:93-7.
- El-Galaly TC, Villa D, Gormsen LC, Baech J, Lo A, Cheah CY. FDG-PET/CT in the management of lymphomas: current status and future directions. J Intern Med. 2018;284:358-76.
- Barrington SF, Kirkwood AA, Franceschetto A, Fulham MJ, Roberts TH, Almquist H et al. PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. Blood. 2016;127:1531-38.
- Kawada K, Iwamoto M, Sakai Y. Mechanisms underlying 18F-fluorodeoxyglucose accumulation in colorectal cancer. World J Radiol. 2016;8:880.
- Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328-54.
- Kinahan PE, Fletcher JW. Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. Semin Ultrasound CT MR. 2010;31:496-05.
- Jun Z, Yi S, Jianjun J, Jieping S, Zhiwen Y, Qingyuan M. Comparison of various PET metabolic parameters between left and right-sided colon cancer. J Nucl Med. 2018;59(supplement 1):1397.
